Only then will the promise of a regional market provide a sufficiently realistic incentive for originator companies to agree to make their products available at prices affordable in the region. It will also be important for the countries of the region to agree upon the choice of local producer(s) of any given drug. Depending on its patent status in the exporting country, the foreign generic producer may manufacture the drug under a compulsory license and export it under the draft Article 31 bis, TRIPS Agreement system.